SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

SELLAS Life Sciences Group Inc.

An announcement from Solstice Minerals Limited ( ($AU:SLS) ) is now available. Solstice Minerals Limited announced the issuance of new unquoted equ...

Solstice Minerals Issues New Equity Securities for Employee Incentive

Solaris Resources ( ($TSE:SLS) ) has shared an announcement. Solaris Resources Inc. has released its condensed consolidated interim financial state...

Solaris Resources Reports Q3 2025 Financial Results

Solstice Minerals Limited ( ($AU:SLS) ) has shared an update. Solstice Minerals Limited announced significant growth through systematic exploration...

Solstice Minerals Limited Reports Significant Growth and Strategic Acquisitions

BMO Capital analyst Rene Cartier maintained a Buy rating on Solaris Resources yesterday and set a price target of C$14.00. The company’s shares ope...

Solaris Resources (SLSR) Receives a Buy from BMO Capital

SELLAS Life Sciences Group ( ($SLS) ) just unveiled an announcement. On October 24, 2025, SELLAS Life Sciences Group entered into a Warrant Inducem...

Current Quarter	$NA	Next Quarter	$NA
Current Year	$-0.28	Next Year	$-0.38
QoQ Growth	NaN%	YoY Growth	-35.7%
3Y EPS CAGR	+28.0%	Target Price	$6.83
Consensus	Buy	Upside	+346.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SLS	$1.53	+4.79%	2.97M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SLS	$1.53	+4.8%	2.97M
3
4
5
6

SLS

SLS

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get SELLAS Life Sciences Group Inc. Data in Excel

Get SELLAS Life Sciences Group Inc. Data in Excel